메뉴 건너뛰기




Volumn 336, Issue 3, 2011, Pages 801-808

In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies

Author keywords

[No Author keywords available]

Indexed keywords

AZILSARTAN; INOSITOL PHOSPHATE; IRBESARTAN; OLMESARTAN; TELMISARTAN; VALSARTAN;

EID: 79951979674     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.176636     Document Type: Article
Times cited : (146)

References (40)
  • 2
    • 78651266925 scopus 로고    scopus 로고
    • Effects of the novel angiotensin receptor blocker azilsartan medoxomil in patients with primary hypertension
    • Bakris GL, Sica D, Weber MA, White WB, Perez A, Cao C, and Kupfer S (2010) Effects of the novel angiotensin receptor blocker azilsartan medoxomil in patients with primary hypertension. J Clin Hypertens 12 (Suppl 1):A106-A107.
    • (2010) J Clin Hypertens , vol.12 , Issue.SUPPL. 1
    • Bakris, G.L.1    Sica, D.2    Weber, M.A.3    White, W.B.4    Perez, A.5    Cao, C.6    Kupfer, S.7
  • 4
    • 67449168119 scopus 로고    scopus 로고
    • Binding sites of valsartan, candesartan and losartan with angiotensin II receptor 1 subtype by molecular modeling
    • Bhuiyan MA, Ishiguro M, Hossain M, Nakamura T, Ozaki M, Miura S, and Nagatomo T (2009) Binding sites of valsartan, candesartan and losartan with angiotensin II receptor 1 subtype by molecular modeling. Life Sci 85:136-140.
    • (2009) Life Sci , vol.85 , pp. 136-140
    • Bhuiyan, M.A.1    Ishiguro, M.2    Hossain, M.3    Nakamura, T.4    Ozaki, M.5    Miura, S.6    Nagatomo, T.7
  • 6
    • 0347423198 scopus 로고    scopus 로고
    • Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
    • Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute, and National High Blood Pressure Education Program Coordinating Committee. National Heart, Lung, and Blood Institute, and National High Blood Pressure Education Program Coordinating Committee
    • Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ, Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute, and National High Blood Pressure Education Program Coordinating Committee. National Heart, Lung, and Blood Institute, and National High Blood Pressure Education Program Coordinating Committee(2003) Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42: 1206-1252.
    • (2003) Hypertension , vol.42 , pp. 1206-1252
    • Chobanian, A.V.1    Bakris, G.L.2    Black, H.R.3    Cushman, W.C.4    Green, L.A.5    Izzo Jr., J.L.6    Jones, D.W.7    Materson, B.J.8    Oparil, S.9    Wright Jr., J.T.10    Roccella, E.J.11
  • 7
    • 0033824138 scopus 로고    scopus 로고
    • International Union of Pharmacology. XXIII. The angiotensin II receptors
    • de Gasparo M, Catt KJ, Inagami T, Wright JW, and Unger T (2000) International Union of Pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 52:415-472.
    • (2000) Pharmacol Rev , vol.52 , pp. 415-472
    • De Gasparo, M.1    Catt, K.J.2    Inagami, T.3    Wright, J.W.4    Unger, T.5
  • 8
    • 0036271824 scopus 로고    scopus 로고
    • Candesartan cilexetil: An update of its use in essential hypertension
    • Easthope SE and Jarvis B (2002) Candesartan cilexetil: an update of its use in essential hypertension. Drugs 62:1253-1287. (Pubitemid 34591101)
    • (2002) Drugs , vol.62 , Issue.8 , pp. 1253-1287
    • Easthope, S.E.1    Jarvis, B.2
  • 11
    • 0030480485 scopus 로고    scopus 로고
    • Synthesis and angiotensin II receptor antagonistic activities of benzimidazole derivatives bearing acidic heterocycles as novel tetrazole bioisosteres
    • DOI 10.1021/jm960547h
    • Kohara Y, Kubo K, Imamiya E, Wada T, Inada Y, and Naka T (1996) Synthesis and angiotensin II receptor antagonistic activities of benzimidazole derivatives bearing acidic heterocycles as novel tetrazole bioisosteres. J Med Chem 39:5228-5235. (Pubitemid 27010313)
    • (1996) Journal of Medicinal Chemistry , vol.39 , Issue.26 , pp. 5228-5235
    • Kohara, Y.1    Kubo, K.2    Imamiya, E.3    Wada, T.4    Inada, Y.5    Naka, T.6
  • 12
    • 70349980161 scopus 로고    scopus 로고
    • Next generation multifunctional angiotensin receptor blockers
    • Kurtz TW and Klein U (2009) Next generation multifunctional angiotensin receptor blockers. Hypertens Res 32:826-834.
    • (2009) Hypertens Res , vol.32 , pp. 826-834
    • Kurtz, T.W.1    Klein, U.2
  • 13
    • 0026510753 scopus 로고
    • Evidence that the apparent complexity of receptor antagonism by angiotensin II analogues is due to a reversible and syntopic action
    • Liu YJ, Shankley NP, Welsh NJ, and Black JW (1992) Evidence that the apparent complexity of receptor antagonism by angiotensin II analogues is due to a reversible and syntopic action. Br J Pharmacol 106:233-241.
    • (1992) Br J Pharmacol , vol.106 , pp. 233-241
    • Liu, Y.J.1    Shankley, N.P.2    Welsh, N.J.3    Black, J.W.4
  • 17
    • 0025884056 scopus 로고
    • Efficient selection for high-expression transfectants with a novel eukaryotic vector
    • Niwa H, Yamamura K, and Miyazaki J (1991) Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108:193-199.
    • (1991) Gene , vol.108 , pp. 193-199
    • Niwa, H.1    Yamamura, K.2    Miyazaki, J.3
  • 21
    • 0033950686 scopus 로고    scopus 로고
    • Newly emerging pharmacologic differences in angiotensin II receptor blockers
    • Oparil S (2000) Newly emerging pharmacologic differences in angiotensin II receptor blockers. Am J Hypertens 13:18S-24S.
    • (2000) Am J Hypertens , vol.13
    • Oparil, S.1
  • 22
    • 0034760610 scopus 로고    scopus 로고
    • Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension
    • Oparil S, Williams D, Chrysant SG, Marbury TC, and Neutel J (2001) Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens 3:283-291, 318.
    • (2001) J Clin Hypertens , vol.3
    • Oparil, S.1    Williams, D.2    Chrysant, S.G.3    Marbury, T.C.4    Neutel, J.5
  • 23
    • 0029078461 scopus 로고
    • Functional studies but not receptor binding can distinguish surmountable from insurmountable AT1 antagonism
    • Panek RL, Lu GH, Overhiser RW, Major TC, Hodges JC, and Taylor DG (1995) Functional studies but not receptor binding can distinguish surmountable from insurmountable AT1 antagonism. J Pharmacol Exp Ther 273:753-761.
    • (1995) J Pharmacol Exp Ther , vol.273 , pp. 753-761
    • Panek, R.L.1    Lu, G.H.2    Overhiser, R.W.3    Major, T.C.4    Hodges, J.C.5    Taylor, D.G.6
  • 24
    • 0034691035 scopus 로고    scopus 로고
    • Systematic identification of mutations that constitutively activate the angiotensin II type 1A receptor by screening a randomly mutated cDNA library with an original pharmacological bioassay
    • DOI 10.1073/pnas.110142297
    • Parnot C, Bardin S, Miserey-Lenkei S, Guedin D, Corvol P, and Clauser E (2000) Systematic identification of mutations that constitutively activate the angiotensin II type 1A receptor by screening a randomly mutated cDNA library with an original pharmacological bioassay. Proc Natl Acad Sci USA 97:7615-7620. (Pubitemid 30431512)
    • (2000) Proceedings of the National Academy of Sciences of the United States of America , vol.97 , Issue.13 , pp. 7615-7620
    • Parnot, C.1    Bardin, S.2    Miserey-Lenkei, S.3    Guedin, D.4    Corvol, P.5    Clauser, E.6
  • 25
    • 70349987109 scopus 로고    scopus 로고
    • Multivalent ligand-receptor interactions elicit inverse agonist activity of AT1 receptor blockers against stretch-induced AT1 receptor activation
    • Qin Y, Yasuda N, Akazawa H, Ito K, Kudo Y, Liao CH, Yamamoto R, Miura S, Saku K, and Komuro I (2009) Multivalent ligand-receptor interactions elicit inverse agonist activity of AT1 receptor blockers against stretch-induced AT1 receptor activation. Hypertens Res 32:875-883.
    • (2009) Hypertens Res , vol.32 , pp. 875-883
    • Qin, Y.1    Yasuda, N.2    Akazawa, H.3    Ito, K.4    Kudo, Y.5    Liao, C.H.6    Yamamoto, R.7    Miura, S.8    Saku, K.9    Komuro, I.10
  • 26
    • 48549095799 scopus 로고    scopus 로고
    • Angiotensin receptor blockers: Current status and future prospects
    • Ram CV (2008) Angiotensin receptor blockers: current status and future prospects. Am J Med 121:656-663.
    • (2008) Am J Med , vol.121 , pp. 656-663
    • Ram, C.V.1
  • 27
    • 0027744344 scopus 로고
    • 6-Substituted benzimidazoles as new nonpeptide angiotensin II receptor antagonists: Synthesis, biological activity, and structure-activity relationships
    • Ries UJ, Mihm G, Narr B, Hasselbach KM, Wittneben H, Entzeroth M, van Meel JC, Wienen W, and Hauel NH (1993) 6-Substituted benzimidazoles as new nonpeptide angiotensin II receptor antagonists: synthesis, biological activity, and structure-activity relationships. J Med Chem 36:4040-4051.
    • (1993) J Med Chem , vol.36 , pp. 4040-4051
    • Ries, U.J.1    Mihm, G.2    Narr, B.3    Hasselbach, K.M.4    Wittneben, H.5    Entzeroth, M.6    Van Meel, J.C.7    Wienen, W.8    Hauel, N.H.9
  • 28
    • 44949171907 scopus 로고    scopus 로고
    • Olmesartan medoxomil: A review of its use in the management of hypertension
    • DOI 10.2165/00003495-200868090-00005
    • Scott LJ and McCormack PL (2008) Olmesartan medoxomil: a review of its use in the management of hypertension. Drugs 68:1239-1272. (Pubitemid 351822113)
    • (2008) Drugs , vol.68 , Issue.9 , pp. 1239-1272
    • Scott, L.J.1    McCormack, P.L.2
  • 29
    • 0027431141 scopus 로고
    • Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2′-(1H-tetrazol-5-yl)biphenyl-4-yl] methyl]-1H-benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, (+/)-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[[2′-(1H-tetrazol-5-yl) biphenyl-4-yl] methyl]-1H-benzimidazole-7-carboxylate (TCV-116)
    • Shibouta Y, Inada Y, Ojima M, Wada T, Noda M, Sanada T, Kubo K, Kohara Y, Naka T, and Nishikawa K (1993) Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2′-(1H- tetrazol-5-yl)biphenyl-4-yl] methyl]-1H-benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, (+/)-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[[2′-(1H-tetrazol-5-yl)biphenyl-4-yl] methyl]-1H-benzimidazole- 7-carboxylate (TCV-116). J Pharmacol Exp Ther 266:114-120.
    • (1993) J Pharmacol Exp Ther , vol.266 , pp. 114-120
    • Shibouta, Y.1    Inada, Y.2    Ojima, M.3    Wada, T.4    Noda, M.5    Sanada, T.6    Kubo, K.7    Kohara, Y.8    Naka, T.9    Nishikawa, K.10
  • 31
    • 44949104716 scopus 로고    scopus 로고
    • Comparison of angiotensin II type 1 receptor antagonists in the treatment of essential hypertension
    • Smith DH (2008) Comparison of angiotensin II type 1 receptor antagonists in the treatment of essential hypertension. Drugs 68:1207-1225.
    • (2008) Drugs , vol.68 , pp. 1207-1225
    • Smith, D.H.1
  • 32
    • 70449484613 scopus 로고    scopus 로고
    • The evolving story of the RAAS in hypertension, diabetes and CV disease: Moving from macrovascular to microvascular targets
    • Steckelings UM, Rompe F, Kaschina E, and Unger T (2009) The evolving story of the RAAS in hypertension, diabetes and CV disease: moving from macrovascular to microvascular targets. Fundam Clin Pharmacol 23:693-703.
    • (2009) Fundam Clin Pharmacol , vol.23 , pp. 693-703
    • Steckelings, U.M.1    Rompe, F.2    Kaschina, E.3    Unger, T.4
  • 33
    • 62949153839 scopus 로고    scopus 로고
    • Sartan-AT1 receptor interactions: In vitro evidence for insurmountable antagonism and inverse agonism
    • Van Liefde I and Vauquelin G (2009) Sartan-AT1 receptor interactions: in vitro evidence for insurmountable antagonism and inverse agonism. Mol Cell Endocrinol 302:237-243.
    • (2009) Mol Cell Endocrinol , vol.302 , pp. 237-243
    • Van Liefde, I.1    Vauquelin, G.2
  • 34
    • 73649209211 scopus 로고
    • Cumulative dose-response curves. II. Technique for the making of dose-response curves in isolated organs and the evaluation of drug parameters
    • van Rossum JM (1963) Cumulative dose-response curves. II. Technique for the making of dose-response curves in isolated organs and the evaluation of drug parameters. Arch Int Pharmacodyn 143:299-330.
    • (1963) Arch Int Pharmacodyn , vol.143 , pp. 299-330
    • Van Rossum, J.M.1
  • 35
    • 0035254652 scopus 로고    scopus 로고
    • A two-state receptor model for the interaction between angiotensin II type 1 receptors and non-peptide antagonists
    • DOI 10.1016/S0006-2952(00)00546-3, PII S0006295200005463
    • Vauquelin G, Morsing P, Fierens FL, De Backer JP, and Vanderheyden PM (2001) A two-state receptor model for the interaction between angiotensin II type 1 receptors and non-peptide antagonists. Biochem Pharmacol 61:277-284. (Pubitemid 32126665)
    • (2001) Biochemical Pharmacology , vol.61 , Issue.3 , pp. 277-284
    • Vauquelin, G.1    Morsing, P.2    Fierens, F.L.P.3    De, B.J.-P.4    Vanderheyden, P.M.L.5
  • 36
    • 0034932549 scopus 로고    scopus 로고
    • A forced titration study of antihypertensive efficacy of candesartan cilexetil in comparison to losartan: CLAIM study II
    • DOI 10.1038/sj.jhh.1001205
    • Vidt DG, White WB, Ridley E, Rahman M, Harris S, Vendetti J, Michelson EL, Wang R, and CLAIM Study Investigators (2001) A forced titration study of antihypertensive efficacy of candesartan cilexetil in comparison to losartan: CLAIM Study II. J Hum Hypertens 15:475-480. (Pubitemid 32640263)
    • (2001) Journal of Human Hypertension , vol.15 , Issue.7 , pp. 475-480
    • Vidt, D.G.1    White, W.B.2    Ridley, E.3    Rahman, M.4    Harris, S.5    Vendetti, J.6    Michelson, E.L.7    Wang, R.8
  • 37
    • 0027070825 scopus 로고
    • Different types of receptor interaction of peptide and nonpeptide angiotensin II antagonists revealed by receptor binding and functional studies
    • Wienen W, Mauz AB, Van Meel JC, and Entzeroth M (1992) Different types of receptor interaction of peptide and nonpeptide angiotensin II antagonists revealed by receptor binding and functional studies. Mol Pharmacol 41:1081-1088. (Pubitemid 23026108)
    • (1992) Molecular Pharmacology , vol.41 , Issue.6 , pp. 1081-1088
    • Wienen, W.1    Mauz, A.B.M.2    Van, M.J.C.A.3    Entzeroth, M.4
  • 38
    • 0030049822 scopus 로고    scopus 로고
    • Nonpeptide angiotensin II receptor antagonists: Synthesis, biological activities, and structure-activity relationships of imidazole-5-carboxylic acids bearing alkyl, alkenyl, and hydroxyalkyl substituents at the 4-position and their related compounds
    • Yanagisawa H, Amemiya Y, Kanazaki T, Shimoji Y, Fujimoto K, Kitahara Y, Sada T, Mizuno M, Ikeda M, Miyamoto S, et al. (1996) Nonpeptide angiotensin II receptor antagonists: synthesis, biological activities, and structure-activity relationships of imidazole-5-carboxylic acids bearing alkyl, alkenyl, and hydroxyalkyl substituents at the 4-position and their related compounds. J Med Chem 39:323-338.
    • (1996) J Med Chem , vol.39 , pp. 323-338
    • Yanagisawa, H.1    Amemiya, Y.2    Kanazaki, T.3    Shimoji, Y.4    Fujimoto, K.5    Kitahara, Y.6    Sada, T.7    Mizuno, M.8    Ikeda, M.9    Miyamoto, S.10


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.